---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-045478"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:53:11.973164+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Aditxt Q3 plan: simplify cap table, cut debt, advance Adimune and Pearsanta

## Summary
- CEO states goal is transition from speculative to growth stage by end of Q3 2025.
- Short-term notes reduced from $8M to $3.5M; focus on paying down obligations.
- Adimune progressing toward human trials; Pearsanta validating endometriosis and prostate cancer assays.
- Pearsanta IPO uncertain due to weak market; timing depends on commercialization progress.
- Company not at earnings stage; still raising capital; no near-term revenue or guidance.

## SEC filing metadata
- accession: 0001213900-25-045478
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025045478/0001213900-25-045478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025045478/ea0242789-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-045478
- JSON: https://secwatch.observer/filing/0001213900-25-045478.json
- Plain text: https://secwatch.observer/filing/0001213900-25-045478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.